Neuroscience of Marijuana Impaired Driving

大麻驾驶障碍的神经科学

基本信息

  • 批准号:
    8990677
  • 负责人:
  • 金额:
    $ 67.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-08-01 至 2020-05-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Driving while intoxicated on cannabis is a major and growing public health problem. Driving safety is an important issue in the United States as more than 3 million persons are reported injured and >40,000 die annually in motor vehicle crashes. Traffic accidents are the greatest single cause of death in 5-32 year-olds; many are due to intoxicated drivers. Cannabis (CNB) is a commonly abused drug whose use cuts across social class, is linked to cognitive impairment, is a major contributor to intoxication-related accidents either alone or with alcohol. However, CNB intoxication is little studied in relation to driving compared to alcohol. Not only does the current NHTSA Strategic Plan for Behavioral Research prioritize understanding how drugs other than alcohol contribute to traffic crashes, it has recentl become more pressing to understand the effects of CNB because of increasing rates of legalized medical and/or recreational use, that will likely result in more CNB intoxicated drivers. Social and legal policy will be unable to effectively address the many concerns about driving safety raised by more frequent and widespread use of CNB without new research to better determine the parameters within which CNB use does, or does not, increase automobile accident risk. Our purpose is to better describe specific, driving-related cognitive impairments caused by acute CNB intoxication, their persistence over time, underlying functional brain anatomy, and relationship to performance on a state-of the art validated simulated driving task in which we have prior experience. In a randomized, counterbalanced, double-blinded fashion, we will administer two CNB doses and placebo of smoked cannabis (paced inhalation using a vaporizer) to 48 regular and 48 occasional cannabis users on 3 separate occasions. Following CNB dosing we will assess cognitive and driving impairment longitudinally for several hours using a combination of fMRI and neuropsychological tests, to clarify relationships between subjective and objective measures of intoxication and of impairment, that include expert assessment of THC and its metabolite levels in blood and saliva.
 描述(由申请人提供):醉酒驾驶大麻是一个主要的、日益严重的公共卫生问题。在美国,驾驶安全是一个重要的问题,据报道,每年有300多万人在机动车撞车事故中受伤,40000人死亡。交通事故是5-32岁青少年死亡的最大单一原因;许多是由于醉酒司机造成的。大麻(CNB)是一种常见的滥用药物,其使用跨越社会阶层,与认知障碍有关,是单独或与酒精一起醉酒引发事故的主要原因。然而,与酒精相比,CNB中毒与驾驶的关系研究很少。目前的NHTSA行为研究战略计划不仅将了解酒精以外的药物如何导致交通事故列为优先事项,而且最近也变得更加迫切地了解CNB的影响,因为合法医疗和/或娱乐使用的比率增加,这可能会导致更多CNB醉酒司机。 如果没有新的研究来更好地确定使用CNB会增加或不会增加汽车事故风险的参数,社会和法律政策将无法有效地解决因更频繁和更广泛地使用CNB而引起的许多对驾驶安全的担忧。我们的目的是更好地描述由急性CNB中毒引起的特定的、与驾驶相关的认知障碍,它们随时间的持续,潜在的大脑功能解剖,以及与我们先前经验的最先进验证的模拟驾驶任务的表现的关系。我们将以随机、平衡、双盲的方式,在3个不同的场合给48名经常吸食大麻的人和48名偶尔吸食大麻的人服用两次CNB剂量和安慰剂的吸烟大麻(使用雾化器进行步调吸入)。在服用CNB后,我们将使用功能磁共振成像和神经心理测试相结合的方法,对认知和驾驶损害进行几个小时的纵向评估,以澄清醉酒和损害的主观和客观措施之间的关系,其中包括对THC及其血液和唾液中代谢物水平的专家评估。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GODFREY D PEARLSON其他文献

GODFREY D PEARLSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GODFREY D PEARLSON', 18)}}的其他基金

3/5 Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS)
3/5 生物标志物/生物型,早期精神病课程和专业服务 (BICEPS)
  • 批准号:
    10683286
  • 财政年份:
    2022
  • 资助金额:
    $ 67.6万
  • 项目类别:
3/5 Selective Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (CLOZAPINE)
B-SNIP Biotype-1 (CLOZAPINE) 中氯氮平的选择性抗精神病反应为 3/5
  • 批准号:
    10396432
  • 财政年份:
    2021
  • 资助金额:
    $ 67.6万
  • 项目类别:
3/5 Selective Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (CLOZAPINE)
B-SNIP Biotype-1 (CLOZAPINE) 中氯氮平的选择性抗精神病反应为 3/5
  • 批准号:
    10613491
  • 财政年份:
    2021
  • 资助金额:
    $ 67.6万
  • 项目类别:
Neuroimaging predictors of bariatric surgical outcomes
减肥手术结果的神经影像预测因素
  • 批准号:
    10180948
  • 财政年份:
    2018
  • 资助金额:
    $ 67.6万
  • 项目类别:
Neuroimaging predictors of bariatric surgical outcomes
减肥手术结果的神经影像预测因素
  • 批准号:
    10430196
  • 财政年份:
    2018
  • 资助金额:
    $ 67.6万
  • 项目类别:
Neuroimaging predictors of bariatric surgical outcomes
减肥手术结果的神经影像预测因素
  • 批准号:
    9981729
  • 财政年份:
    2018
  • 资助金额:
    $ 67.6万
  • 项目类别:
Neuroscience of Marijuana Impaired Driving
大麻驾驶障碍的神经科学
  • 批准号:
    9930252
  • 财政年份:
    2015
  • 资助金额:
    $ 67.6万
  • 项目类别:
3/4-Psychosis & Affective Research Domains and Intermediate Phenotypes (PARDIP)
3/4-精神病
  • 批准号:
    8504331
  • 财政年份:
    2013
  • 资助金额:
    $ 67.6万
  • 项目类别:
3/4-Psychosis & Affective Research Domains and Intermediate Phenotypes (PARDIP)
3/4-精神病
  • 批准号:
    8917630
  • 财政年份:
    2013
  • 资助金额:
    $ 67.6万
  • 项目类别:
3/4-Psychosis & Affective Research Domains and Intermediate Phenotypes (PARDIP)
3/4-精神病
  • 批准号:
    8706966
  • 财政年份:
    2013
  • 资助金额:
    $ 67.6万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.6万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.6万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 67.6万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.6万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.6万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.6万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.6万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 67.6万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 67.6万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 67.6万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了